The effect of dopamine on conditioned placebo analgesia in healthy individuals: a double-blind randomized trial
- 140 Downloads
Better means to control placebo effects are key to optimizing treatment outcomes. Dopamine-based reward and learning mechanisms have been hypothesized to drive placebo effects. Here, we tested whether dopamine augmentation can modulate learned placebo effects.
We performed a randomized, double-blind parallel group study with 70 healthy adult participants to test whether a single oral dose of the dopamine precursor levodopa/carbidopa (100/25 mg) administered before the acquisition of conditioned placebo analgesia enhances the placebo response in an established experimental placebo model using heat pain.
Overall, the observed levels of placebo analgesia in our sample were low and not statistically significant. Levodopa, compared to placebo, only led to a marginal increase in placebo analgesia. Female participants tended to show larger placebo responses than male participants. Within the female subgroup, levodopa showed small-to-moderate effects on placebo analgesia; however, this effect was not statistically significant.
In summary, the present study could not provide evidence for a placebo augmenting effect of levodopa-enhanced dopamine levels in healthy subjects. Further studies are needed to elucidate whether placebo enhancement can be achieved through dopamine augmentation.
KeywordsHuman Placebo Analgesia l-DOPA Conditioning Experimental pain
Compliance with ethical standards
Conflicts of interest
The authors declare that they have no conflict of interest.
- Becker S, Ceko M, Louis-Foster M, Elfassy NM, Leyton M, Shir Y, Schweinhardt P (2013a) Dopamine and pain sensitivity: neither sulpiride nor acute phenylalanine and tyrosine depletion have effects on thermal pain sensations in healthy volunteers. PLoS One 8:1–10. https://doi.org/10.1371/journal.pone.0080766 CrossRefGoogle Scholar
- Guitart-Masip M, Economides M, Huys QJM, Frank MJ, Chowdhury R, Duzel E, Dayan P, Dolan RJ (2014) Differential, but not opponent, effects of l-DOPA and citalopram on action learning with reward and punishment. Psychopharmacology 231:955–966. https://doi.org/10.1007/s00213-013-3313-4 CrossRefPubMedPubMedCentralGoogle Scholar
- Lehr D, Hillert A, Schmitz E, Sosnowsky N (2008) Screening depressiver Störungen mittels Allgemeiner Depressions-Skala (ADS-K) und State-Trait Depressions Scales (STDS-T). Eine vergleichende Evaluation von Cut-Off-Werten. Diagnostica 54:61–70. https://doi.org/10.1026/0012-1924.54.1. CrossRefGoogle Scholar
- Lidstone SC, Schulzer M, Dinelle K (2011) Effects of expectation on placebo-induced dopamine release in Parkinson’s disease. Focus Park Dis 22:22–24Google Scholar
- Nyholm D, Lewander T, Gomes-Trolin C, Bäckström T, Panagiotidis G, Ehrnebo M, Nyström C, Aquilonius SM (2012) Pharmacokinetics of levodopa/carbidopa microtablets versus levodopa/benserazide and levodopa/carbidopa in healthy volunteers. Clin Neuropharmacol 35:111–117. https://doi.org/10.1097/WNF.0b013e31825645d1 CrossRefGoogle Scholar
- Puig MV, Antzoulatos EG, Miller EK (2014) Prefrontal dopamine in associative learning and memory. Neuroscience 282:217–229. https://doi.org/10.1016/j.neuroscience.2014.09.026 CrossRefPubMedPubMedCentralGoogle Scholar